NasdaqGS:PHATPharmaceuticals
Could Expanding VOQUEZNA’s Pipeline Mark a New Strategic Phase for Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals recently announced that the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for treating eosinophilic esophagitis (EoE) in adults, with topline results expected in 2027.
This development highlights the company’s commitment to expanding VOQUEZNA’s potential indications, targeting a condition with significant unmet medical need and complex diagnosis challenges.
We'll explore how advancing VOQUEZNA into Phase 2 for EoE may...